OGEN · Insider Trading
Oragenics Inc.
Every open-market purchase and sale reported by OGEN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-07 | John Spencer | Chief Financial Officer | A | +55,900 deriv. | — |
| 2026-01-22 | Fred Telling | Director | Sell | −210 | −$198 |
| 2025-12-15 | Alan W Dunton | Director | A | +125,000 deriv. | — |
| 2025-12-15 | Charles L Pope | Director | A | +125,000 deriv. | — |
| 2025-12-15 | Robert C Koski | Director | A | +125,000 deriv. | — |
| 2025-12-15 | Janet Huffman | CEO and CFO | A | +250,000 deriv. | — |
| 2025-12-15 | Natasha Giordano | Director | A | +163,320 deriv. | — |
| 2025-12-15 | John P Gandolfo | Director | A | +125,000 deriv. | — |
| 2025-12-15 | Fred Telling | Director | Sell | −210 | −$198 |
| 2025-06-18 | Odyssey Health, Inc. | 10%+ Owner | Sell | −7,044 | −$30.41K |
| 2025-06-16 | Odyssey Health, Inc. | 10%+ Owner | Sell | −10,000 | −$43.60K |
| 2024-12-13 | Robert C Koski | Director | C | +5,000 | — |
| 2024-12-09 | Alan W Dunton | Director | Sell | −66 | −$24 |
| 2024-12-09 | Fred Telling | Director | Sell | −3,597 | −$1.29K |
| 2024-09-20 | Alan W Dunton | Director | A | +65,000 deriv. | — |
| 2024-09-20 | John P Gandolfo | Director | A | +45,000 deriv. | — |
| 2024-09-20 | Fred Telling | Director | A | +65,000 deriv. | — |
| 2024-09-20 | Kimberly M Murphy | Director | A | +27,083 deriv. | — |
| 2024-09-20 | Robert C Koski | Director | A | +65,000 deriv. | — |
| 2024-09-20 | Bruce A. Cassidy Sr. | Director | A | +45,000 deriv. | — |
| 2024-09-20 | Janet Huffman | Chief Financial Officer | A | +80,000 deriv. | — |
| 2024-09-20 | Charles L Pope | Director | A | +100,000 deriv. | — |
| 2024-09-20 | J Michael Redmond | President | A | +100,000 deriv. | — |
| 2024-01-02 | J Michael Redmond | President | A | +75,000 deriv. | — |
| 2023-12-01 | Fred Telling | Director | Sell | −3,500 | −$12.49K |
| 2023-10-06 | John P Gandolfo | Director | A | +5,102 deriv. | — |
| 2023-10-06 | Bruce A. Cassidy Sr. | Director | A | +5,102 deriv. | — |
| 2023-08-10 | Charles L Pope | Director | A | +25,000 | — |
| 2023-08-10 | Alan W Dunton | Director | A | +25,000 | — |
| 2023-08-10 | Janet Huffman | CFO, Secretary and Treasurer | A | +15,000 | — |
| 2023-08-10 | Robert C Koski | Director | A | +25,000 | — |
| 2023-08-10 | Fred Telling | Director | A | +25,000 | — |
| 2023-08-10 | Kimberly M Murphy | CEO and President | A | +25,000 | — |
| 2023-03-08 | Janet Huffman | CFO, Secretary and Treasurer | A | +7,000 deriv. | — |
| 2023-01-03 | Robert C Koski | Director | Sell | −79,005 | −$8.35K |
| 2022-12-16 | Robert C Koski | Director | Sell | −165,497 | −$29.07K |
| 2022-12-15 | Robert C Koski | Director | Sell | −4,503 | −$788 |
| 2022-12-12 | Robert C Koski | Director | Sell | −48,795 | −$9.61K |
| 2022-12-09 | Robert C Koski | Director | Sell | −13,036 | −$2.61K |
| 2022-12-01 | Robert C Koski | Director | Sell | −400,000 | −$76.68K |
| 2022-08-02 | Fred Telling | Director | A | +220,000 deriv. | — |
| 2022-08-02 | Robert C Koski | Director | A | +220,000 deriv. | — |
| 2022-08-02 | Alan W Dunton | Director | A | +220,000 deriv. | — |
| 2022-08-02 | Michael O'Keefe Sullivan | Chief Financial Officer | A | +200,000 deriv. | — |
| 2022-08-02 | Charles L Pope | Director | A | +220,000 deriv. | — |
| 2022-06-27 | Fred Telling | Director | A | +250,000 deriv. | — |
| 2022-06-24 | Fred Telling | Director | A | +250,000 deriv. | — |
| 2022-06-24 | Kimberly M Murphy | CEO and President | A | +800,000 deriv. | — |
| 2022-06-24 | Michael O'Keefe Sullivan | Chief Financial Officer | A | +250,000 deriv. | — |
| 2022-06-21 | Fred Telling | Director | Buy | +10,084 | +$2.88K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Odyssey Health, Inc. | 10%+ Owner | 5,044 | $2.01K |
| Robert C Koski | Director | 1,710 | $681 |
| Fred Telling | Director | 948 | $378 |
| Alan W Dunton | Director | 854 | $340 |
| Charles L Pope | Director | 849 | $338 |
| Janet Huffman | CEO and CFO | 500 | $199 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the OGEN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.